Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 27Philadelphia Chromosome 3Leukemia, Myeloid, Chronic-Phase 3Leukemia 3Blast Crisis 3Bronchiolitis Obliterans Syndrome 2Translocation, Genetic 1Pathologic Processes 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Hematologic Diseases 1Breast Neoplasms 1Bone Marrow Diseases 1

Interventions

ponatinib 4fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Imatinib Mesylate 2Cyclophosphamide 2Busulfan 2Bone Marrow Transplantation 2trametinib 1ruxolitinib 1nilotinib 1dabrafenib 1cobimetinib 1bosutinib 1Vemurafenib 1CPI-0610 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × bosutinib × Myeloid × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡